Company intelligence / Profile preview

7OHMZ

Ownership: Private
Development stage: Commercial

Overview

7OHMZ produces lab-tested tablets containing concentrated 7-Hydroxymitragynine ("7-OHM"), an active metabolite of mitragynine from kratom. The products are marketed for focus, relaxation, and natural wellness. All batches are tested for potency and purity with COA provided. These products are not pharmaceuticals but rather advanced kratom-derived supplements intended for experienced users seeking consistent effects.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule (specifically botanical alkaloid extract)Tablet formulation of botanical alkaloids (primarily 7-Hydroxymitragynine)
Industry: Food & Nutrition

Drug pipeline

3 assets

7-hydroxymitragynine tablets

Commercial

Indications: Pain

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on 7OHMZ.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7OHMZ.

Explore the full profile